TSPAN31 Activates Fatty Acid Metabolism and PI3K/AKT Pathway to Promote Tumor Progression in Breast Cancer

被引:0
|
作者
Luo, Wenquan [1 ]
Sun, Yuxiang [1 ]
Cao, Liang [2 ]
机构
[1] Feicheng Peoples Hosp, Breast & Thyroid Surg Dept, Feicheng, Shandong, Peoples R China
[2] Taian Tumor Prevent & Treatment Hosp, Radiotherapy Dept, Tai An, Shandong, Peoples R China
关键词
breast cancer; cell proliferation; fatty acid metabolism; PI3K/AKT pathway; TSPAN31; CELLS; GROWTH; SYNTHASE;
D O I
10.1002/mc.23912
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer (BC) is one of the most common human malignancies, but the mechanisms of BC have not been fully elucidated. Recently, tetraspanin 31 (TSPAN31) is reported to be linked to cancer progression. However, the function of TSPAN31 remains unclear in BC. Investigation of the function and potential mechanism of TSPAN31 in BC was the purpose of this study. Immunohistochemistry, western blot, and quantitative real-time polymerase chain reaction were applied to measure TSPAN31 expression. Loss and gain functional experiments were utilized to survey the influences of TSPAN31 on BC biological process, including cell growth, invasion, migration, and fatty acid metabolism. Mechanistically, Kyoto Encyclopedia of Genes and Genomes analysis based on DepMap database and Gene Set Enrichment Analysis based on The Cancer Genome Atlas database were executed to find TSPAN31-related pathway. Western blot was carried out to assess the changes of fatty acid synthase (FASN), sterol regulatory element binding protein 1 (SREBP1), acyl-CoA synthetase long-chain family member 1 (ACSL1), phosphatidylinositol 3-kinase (PI3K), phosphorylated (p)-PI3K, protein kinase B (AKT), and p-AKT. In human non-triple negative breast cancer tissues and cells, TSPAN31 expression was upregulated. TSPAN31 knockdown induced BC cell apoptosis, inhibited cell proliferation, invasion, migration, and fatty acid metabolism, and reduced the protein levels of FASN, SREBP1, ACSL1, p-PI3K/PI3K, and p-AKT/AKT. In contrast, TSPAN31 overexpression led to the opposite results. Additionally, the activator of PI3K (740 Y-P) attenuated the inhibition of TSPAN31 knockdown on fatty acid metabolism, proliferation, and invasion in BC cells. Through activation of fatty acid metabolism and PI3K/AKT pathway, TSPAN31 played a carcinogenic role in BC. For the mechanism of BC tumorigenesis, our study provides an interesting insight.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5
    Xiaoying Jin
    Dandan Wang
    Mengxia Lei
    Yan Guo
    Yuqing Cui
    Fengzhi Chen
    Weiling Sun
    Xuesong Chen
    Journal of Translational Medicine, 20
  • [32] Novel tumor suppressor regulating the PI3K/AKT pathway in triple negative breast cancer (TNBC)
    Chan, Stefanie
    Smith, Emma
    Monti, Stefano
    Cardamone, M. Dafne
    Perissi, Valentina
    CANCER RESEARCH, 2020, 80 (04)
  • [33] Tetraspanin 1 (TSPAN1) promotes growth and transferation of breast cancer cells via mediating PI3K/Akt pathway
    Wu, Yange
    Chen, Wenxiu
    Gong, Yufeng
    Liu, Hongxia
    Zhang, Bo
    BIOENGINEERED, 2021, 12 (02) : 10761 - 10770
  • [34] The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
    Paplomata, Elisavet
    O'Regan, Ruth
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (04) : 154 - 166
  • [35] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    Woo, S-U
    Sangai, T.
    Akcakanat, A.
    Chen, H.
    Wei, C.
    Meric-Bernstam, F.
    ONCOGENESIS, 2017, 6 : e385 - e385
  • [36] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    S-U Woo
    T Sangai
    A Akcakanat
    H Chen
    C Wei
    F Meric-Bernstam
    Oncogenesis, 2017, 6 : e385 - e385
  • [37] Involvement of PI3K/Akt pathway alterations in breast cancer treated with trastuzumab
    Fernandez Garcia, M.
    Centeno Ramos, I.
    Suarez Fernandez, L.
    Fuentes, N.
    Vivanco Allende, B.
    Garcia Pravia, C.
    Balbin Felechosa, M.
    Fresno Forcelledo, M. F.
    VIRCHOWS ARCHIV, 2012, 461 : S240 - S241
  • [38] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [39] Clinical development of PI3K/AKT pathway inhibitors in breast cancer.
    Derynck, Mika
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 22 - 22
  • [40] Targeting PI3K/AKT pathway in triple-negative breast cancer
    Delaloge, Suzette
    DeForceville, Louise
    LANCET ONCOLOGY, 2017, 18 (10): : 1293 - 1294